2014
DOI: 10.1111/odi.12240
|View full text |Cite
|
Sign up to set email alerts
|

Hepatitis C virus: a silent killer relevant to dentistry

Abstract: Around 25 years ago, hepatitis C virus (HCV) was identified, and following intense research and tremendous advancements, the infection is now potentially curable and even complete viral eradication is possible. It is also evident that HCV can be involved in some oral disorders, but more research is clearly warranted on oral health of HCV-infected patients. Given the global estimates on HCV epidemic and its likely huge economic impact, primary prevention and secondary prevention are worldwide priorities. Howeve… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 60 publications
(64 reference statements)
0
3
0
Order By: Relevance
“…Research has demonstrated a strong association between HCV infection and OLP, which is explained by the ability of the virus to replicate in oral mucosa cells and attract HCV-specific T lymphocytes [ 28 ]. Furthermore, HCV is an oncogenic virus and might be involved in oral carcinogenesis [ 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Research has demonstrated a strong association between HCV infection and OLP, which is explained by the ability of the virus to replicate in oral mucosa cells and attract HCV-specific T lymphocytes [ 28 ]. Furthermore, HCV is an oncogenic virus and might be involved in oral carcinogenesis [ 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Research has demonstrated a strong association between HCV infection and OLP, which is explained by the ability of the virus to replicate in oral mucosa cells and attract HCV-speci c T lymphocytes [19]. Furthermore, HCV is an oncogenic virus and might be involved in oral carcinogenesis [20].…”
Section: Discussionmentioning
confidence: 99%
“…20 In 2003, the first-in-human data on a direct antiviral agent (DAA) for HCV were published, and in 2011, the HCV protease inhibitors telaprevir and boceprevir were approved by the US Food and Drug Administration. 28 In 2014, three new HCV DAAs (Sofosbuvir, Simeprevir, and Daclatasvir) were licensed worldwide for use as IFN-free.…”
Section: Last Pieces Of the Jigsawmentioning
confidence: 99%